Abstract
In this chapter, we will present and discuss the challenges of assessing oncology products from a health economic perspective. We will provide a brief introduction on the need for economic evaluation in health care and focus on cost-effectiveness and comparative aspects of the evaluation of oncology products, which are of paramount interest to HTA decision-making bodies using economic evaluation in their decision-making framework. As the burden of oncology is well-documented, we do not discuss it in detail here. Before we address the specific issue of oncology, we will briefly define the critical aspects of HTA assessment and also define what a cost-effectiveness analysis is and why economic modelling is the most appropriate tool to assess the cost-effectiveness of oncology products. We will touch upon the prices of oncology drugs and the questions that high prices raise regarding funding and availability. We then present an overview of the general structure of an oncology cost-effectiveness model. Usually, this is quite simple, representing response, progression, advanced-stage disease and death. Despite the relative simplicity of these models, some issues may render the evaluation more complex; we will touch upon these in this chapter:
-
Issue with clinical inputs due to the design of randomised clinical trials (e.g. cross-over designs involving a treatment switch)
-
Need for survival extrapolation and limitations of current parametric models
-
Rare conditions with limited economic and comparative evidence available
-
High pace of clinical development
Finally, we will conclude with a discussion of the uncertainty around the evaluation of oncology products and the major evolution expected in health economics in oncology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Annemans L (2018) Extrapolation in oncology modelling: novel methods for novel compounds. Available from: https://www.ispor.org/news/articles/Aug12/Extrapolation-in-Oncology-Modelling.asp. Accessed on 09 Feb 2018
Bai Y, Xu Y, Wu B (2017) Cost-effectiveness and budget impact analysis of apatinib for advanced metastatic gastric cancer from the perspective of health insurance system. Gastroenterol Res Pract 2017:2816737
Califf RM, Zarin DA, Kramer JM et al (2012) Characteristics of clinical trials registered in ClinicalTrials.gov, 2007â2010. Jama 307:1838â1847
Cohen D (2017) Most drugs paid for by ÂŁ1.27bn cancer drugs fund had no âmeaningful benefitâ. BMJ 357:j2097. https://doi.org/10.1136/bmj.j2097
Collins M, Latimer N (2013) NICEâs end of life criteria: who gains, who loses? BMJ 346:f1363
Crabb N, Stevens A (2016) Exploring the assessment and appraisal of regenerative medicines and cell therapy products. NICE
Cressman S, Browman GP, Hoch JS et al (2015) A time-trend economic analysis of cancer drug trials. Oncologist 20:729â736
de Souza JA, Yap BJ, Hlubocky FJ et al (2014) The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 120(20):3245â3253
Dentaland Pharmaceutical Benefits Agency (TLV) (2012) Reimbursement decision for afinitor. TLV, Stockholm, Sweden
Experts in Chronic Myeloid Leukemia (2013) The price of drugs for chronic myeloid leukaemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121(22):4439â4442
Fojo T, Grady C (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 101(15):1044â1048
Gibson E, Koblbauer I, Begum N et al (2017) Modelling the survival outcomes of immuno-oncology drugs in economic evaluations: a systematic approach to data analysis and extrapolation. PharmacoEconomics 35:1257â1270
Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
Isbary G, Staab TR, Amelung VE, Dintsios C-M, Iking-Konert C, Mariotti Nesurini S, Walter M, Ruof J (2017) The effect of crossover in oncology clinical trials on evidence levels in early benefit assessment in Germany. Value Health
Jönsson L, Sandin R, Ekman M, Ransberg J et al (2014) Analyzing overall survival in randomized controlled trials with crossover and implications for economic evaluation. Value Health 17:707â713
Kumar R (2013) Health economics and cost-effectiveness research with special reference to hemato-oncology. Med J Armed Forces India 69(3):273â277
Latimer N (2011) NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trialsâextrapolation with patient-level data. Available from http://www.nicedsu.org.uk. Accessed on 09 Feb 2018
Latimer NR (2013) Survival analysis for economic evaluations alongside clinical trialsâextrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making 33:743â754
Latimer NR, Abrams KR (2014) NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. Available from http://www.nicedsu.org.uk. Accessed on 09 Feb 2018
Marsh K, Xu P, Orfanos P, Gordon J, Griebsch I (2014) Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility. Pharmacoeconomics 32(10):981â993
Miller JD, Foley KA, Russell MW (2014) Current challenges in health economic modelling of cancer therapies: a research inquiry. Am Health Drug Benefits 7:153â162
Murray CJ, Evans DB, Acharya A, Baltussen RM (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9:235â251
National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal. NICE, London
National Institute of Health and Care Excellence (2011) Everolimus for the second-line treatment of advanced renal cell carcinoma (NICE technology appraisal guidance 219). NICE, London, UK
Neumann PJ, Bliss SK, Chambers JD (2012) Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries. Health Aff (Millwood) 31:700â708
âOff-Labelâ indications for oncology drug use and drug compendia: history and current status. J Oncol Pract 1:102â105 (2005)
Oncology Health Economic Modeling Post Progression Working Group of the ISPOR Oncology SIG. ISPOR, Boston (2017)
Prasad V, Mailankody S (2016) The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc 91(6):707â712
Ryder HF, McDonough CF, Tosteson A, Lurie JD (2009) Decision analysis and cost-effectiveness analysis. Semin Spine Surg 21(4):216â222
Sarin R (2008) Criteria for deciding cost-effectiveness for expensive new anti-cancer agents. J Cancer Res Ther 4:1â2
Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13(4):322â338
The Economist. https://www.economist.com/news/finance-and-economics/21736176-progress-developing-treatments-makes-oncology-research-favourite
Toumi M (2017) Introduction to market access for pharmaceuticals. CRC Press
Watkins C, Huang X, Latimer N, Tang Y, Wright EJ (2013) Adjusting overall survival for treatment switches: commonly used methods and practical application. Pharm Stat 12:348â357
Weinstein MC, OâBrien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practicesâmodeling studies. Value Health 6(1):9â17
Zafar SY, Peppercorn JM, Schrag D et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patientâs experience. Oncologist 13(4):381â390
Ziomek J, El Mouaddin N, Ng T et al (2017) Analysis of recent approvals of immuno-oncology drugs across England, Scotland, Germany and France. Value Health A399âA811
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Francois, C., Zhou, J., Pochopien, M., Achour, L., Toumi, M. (2019). Oncology from an HTA and Health Economic Perspective. In: Walter, E. (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham. https://doi.org/10.1007/978-3-030-01207-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-01207-6_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01206-9
Online ISBN: 978-3-030-01207-6
eBook Packages: MedicineMedicine (R0)